A Phase I/II open label study to assess efficacy and safety of IPH1101 associated with low dose of interleukin 2, as add-on therapy to imatinib in CML patients with residual molecular disease.
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2012
At a glance
- Drugs Interleukin-2; IPH 1101
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Innate Pharma
- 31 Aug 2018 Biomarkers information updated
- 04 Jul 2012 Official title amended and lead trial centre identified as reported by EudraCT.
- 04 Jul 2012 Planned End Date 11 Apr 2009 added as reported by EudraCT.